Atea Pharmaceuticals, Inc.

AVIR

US04683R1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
3.67 ^USD	+1.66%		+0.27%	+20.33%

22/05	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024	CI
14/05	Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Atea Pharmaceuticals, Inc. Announces Resignation of Isaac Cheng as Class III Director

April 19, 2021 at 06:01 pm IST

On April 15, 2021, Isaac Cheng, M.D. tendered his resignation as a Class III director of the Board of Directors of Atea Pharmaceuticals, Inc., effective as of such date.

Latest news about Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024	22/05	CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Transcript : Atea Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27/03	CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	11/01
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours	09/01	MT
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19	09/01	CI
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus	13/11	MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023	02/11	CI
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:10 AM	13/23/13
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
JPMorgan Downgrades Atea Pharmaceuticals to Underweight From Neutral	10/23/10	MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023	09/23/09
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Value-Defensive Index	23/23/23	CI
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index	23/23/23	CI
Atea Pharmaceuticals Doses First Patient in Phase 2 Study of Combination Therapy for Hepatitis C Virus Infection	15/23/15	MT
Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination	15/23/15	CI
Atea Pharmaceuticals Rejects Acquisition Proposal From Tang Capital Partners Affiliate Concentra Biosciences	30/23/30	MT
Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc..	30/23/30	CI

Chart Atea Pharmaceuticals, Inc.

Duration

Period

More charts

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.67 USD

Average target price

4.333 USD

Spread / Average Target

+18.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ATEA PHARMACEUTICALS, INC.	+20.33%	31Cr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr
INSMED INCORPORATED	+77.64%	887.31Cr

Bio Therapeutic Drugs